Get in touchPrescribing informationAE reporting
Prescribing informationAE reporting
HomeNeuroblastoma and the unmet needIndicationHeritage
The QARZIBA® story
Neuroblastoma and the unmet needIndicationHeritage
How QARZIBA® works
How immunotherapy worksQARZIBA®'s mechanism of action
How immunotherapy worksQARZIBA®'s mechanism of action
QARZIBA® efficacy and safety profile
QARZIBA® efficacy dataQARZIBA® safety profile
QARZIBA® efficacy dataQARZIBA® safety profile
Resources
Infusion & administrationDosing calculator
Infusion & administrationDosing calculatorGet in touchPrescribing Information
Terms of usePrivacy policyCookie policyContact
Home
How QARZIBA® works
How immunotherapy works

How immunotherapy works

When trying to combat cancer, harnessing the body’s own immune system can be an effective tool. Whilst a patient’s lymphocytes may be able to attack cancerous growth ordinarily, cancerous cells can develop mechanisms to escape detection and continue to grow.
These include:1

  • Loss of antigenicity
  • Loss of immunogenicity
  • Creating an immunosuppressive environment

Immunotherapy aims to overcome these tumour evasion strategies via several mechanisms, including:2

Cellular therapy – CAR-T

Vaccine therapy

Immunomodulators – cytokines, checkpoint inhibitors

Monoclonal antibodies

QARZIBA® is a chimeric monoclonal IgG1 antibody that targets disialoganglioside 2 (GD2), which is overexpressed on the surface of neuroblastoma tumour cells.3

Other pages in this section

QARZIBA®’s mechanism of action

jamie-bike-path@2x

GL-DNB-2200036 | December 2022

Abbreviations

CAR-T=chimeric antigen receptor T cell therapy.

References

  1. Beatty GL and Gladney WL. Clin Cancer Res 2015; 21 (4): 687–692.
  2. Akkın S et al. Molecules 2021; 26 (11): 3382.
  3. QARZIBA® (dinutuximab beta). Summary of product characteristics.

This is a promotional website created by Recordati Rare Diseases and is intended for HCPs only.